相关实验视频

Updated: Jun 12, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

研究纳米大小的瘤衍生的细胞外囊泡在增强抗PD-1免疫疗法

Hesam Abouali¹, Michelle Przedborski², Mohammad Kohandel²

¹Department of Electrical and Computer Engineering, University of Waterloo, Waterloo, Ontario, Canada. mahla.poudineh@uwaterloo.ca.

|September 25, 2024

概括

瘤衍生的细胞外囊泡 (TDEVs) 影响抗PD1免疫疗法反应. 分析TDEVs和IL-12可能为个性化癌症治疗和监测耐药性提供新的生物标志物.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
系统生物学系统生物学

背景情况:

抗PD1免疫检查点阻塞 (ICB) 提高了癌症存活率,但显示患者的反应变化.
瘤衍生的细胞外囊泡 (TDEVs) 影响瘤微环境,可能导致治疗失败.
了解TDEV的作用对于优化抗PD1免疫治疗至关重要.

研究的目的:

通过系统生物学方法研究TDEVs在抗PD1封锁反应动态中的作用.
确定TDEVs和IL-12作为潜在的液体活检生物标志物,用于预测和监测免疫治疗反应.
建立基于液体活检数据的个性化癌症治疗方案的框架.

主要方法:

系统生物学框架的开发,以分析TDEV对抗PD1 ICB反应的影响.
对TDEV检测和患者查的分析进行审问.
评估TDEVs和IL-12作为治疗反应的潜在生物标志物.

主要成果:

通过TDEV检测和分析,可以帮助选患者接受抗PD1免疫疗法.
TDEVs和IL-12显示出作为抗PD1 ICB反应的液体活检生物标志物的潜力.
系统生物学方法可以将其推广到其他癌症免疫疗法.

结论:

在抗PD1免疫疗法中,TDEV分析是患者分层的一个有希望的策略.
液体活检生物标志物如TDEVs和IL-12可以个性化癌症治疗方案.
将液体活检数据集成到系统生物学模型中,使得适应性免疫治疗策略能够克服耐药性.

更多相关视频

Using Nanoplasmon-Enhanced Scattering and Low-Magnification Microscope Imaging to Quantify Tumor-Derived Exosomes

Using Nanoplasmon-Enhanced Scattering and Low-Magnification Microscope Imaging to Quantify Tumor-Derived Exosomes

Published on: May 24, 2019

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.